2Soulitzis N, Karyotis I, Delakas D, et al. Expression analysis of peptide growth factors VEGF, FGF2, TGFβ1, EGF and IGFI in prostate cancer and benign prostatic hyperplasia [ J ]. Int J Oncol, 2006, 29(2) :305-314.
3Godara G, Cannon GW, Cannon GM Jr, et al. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma [J]. Prostate, 2005, 65(1) :27-34.
4Herrmann E, Bogemann M, Bierer S, et al. The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications[ J]. Expert Rev Anticancer Ther, 2006, 6( 1 ) :73- 81.
5Humez S, Monet M, Legrand G, et al. Epidermal growth factorinduced neumendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells [ J ]. Endocr Relat Cancer, 2006, 13( 1 ) :181-195.
6Chakraborty C, Barbin YP, Chakrabarti S, et al. Endothelin-1 promotes migration and induces elevation of [ Ca^2 + ] i and phosphorylation of MAP kinase of a human extravillous trophoblast cell line [J]. Mol Cell Endocrinol, 2003, 201(1-2) :63-73.
7Granchi S, Brocchi S, Bonaccorsi L, et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens [J]. Prostate, 2001,49(4) :267-277.
8Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate [J]. Nat Med, 1995, 1(9):944-949.
9Nelson JB,Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer [J]. Cancer Res, 1996, 56(4):663- 668.
10Gohji K, Kitazawa S, Tamada H, et al. Expression of endothelin receptor a associated with prostate cancer progression [ J ]. J Urol, 2001, 165(3) :1033-1036.
2Mitsiades N.A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer[J].Cancer Res,2013,73(15):4599-4605.
3Mottet N,Van Damme J,Loulidi S,et al.Intermittent hormonal therapy in the treatment of metastatic prostate cancer:a randomized trial[J].BJU Int,2012,110(9):1262-1269.
4Ryan CJ,Molina A,Li J,et al.Serum androgens as prognostic biomarkers in castration-resistant prostate cancer:results from an analysis of a randomized phase III trial[J].J Clin Oncol,2013,31(22):2791-2798.
5Lunardi A,Ala U,Epping MT,et al.A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer[J].Nat Genet,2013,45(7):747-755.
6Heidenreich A,Bastian PJ,Bellmunt J,et al.EAU guidelines on prostate cancer.Part II:Treatment of advanced,relapsing,and castration-resistant prostate cancer[J].Eur Urol,2014,65(2):467-479.
7Sciarra A,Abrahamsson PA,Brausi M,et al.Intermittent androgen-deprivation therapy in prostate cancer:a critical review focused on phase 3 trials[J].Eur Urol,2013,64(5):722-730.
